11 completed, 3 unknown, 2 terminated. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Completed 11, Unknown 3, Terminated 2 |
Follow Cerebrovascular Accident: new trials by email Literature Review of Cerebrovascular Accident trials Research Report on Cerebrovascular Accident
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke ticagrelor + ASA, Placebo+ASA - Cerebrovascular Accident, Cerebrovascular Accident, Acute | Phase 4 | Completed | Peking University Third Hospital | 13000 | 2017-09-01 | 2021-07-15 |
| Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC) Acenocoumarol, Standard of care - Prosthetic Cardiac Valve Thrombosis, Cerebrovascular Accident | Phase 4 | Unknown | Semmelweis University Heart and Vascular Center | 200 | 2016-07-01 | 2017-01-18 |
| Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome BES (biodegradable polymer biolimus-eluting stent), Prasugel, Clopidogrel - Cardiac Death, Hemorrhage | Phase 4 | Unknown | Chonnam National University Hospital | 1400 | 2014-09-01 | 2015-05-18 |
| EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg), ASA 100 mg qd - Cerebrovascular Accident | Phase 4 | Completed | Boehringer Ingelheim | 551 | 2007-07-01 | 2014-03-19 |
| The Effect of Methylphenidate on Motor Learning in Stroke Patients Methylphenidate - Cerebrovascular Accident | Phase 4 | Terminated | University of Aarhus | 13 | 2006-11-01 | 2008-03-27 |
| Dopaminergic Enhancement of Learning and Memory in Aphasia levodopa - Cerebrovascular Accident, Aphasia | Phase 4 | Completed | University Hospital Muenster | 12 | 2005-01-01 | 2013-10-07 |
| Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Candesartan - Cerebrovascular Accident, Acute Stroke | Phase 4 | Unknown | City Hospitals Sunderland NHS Foundation Trust | 50 | 2004-12-01 | 2006-09-13 |
| Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm Botulinum toxin type A, Placebo - Cerebrovascular Accident, Muscle Spasticity | Phase 4 | Completed | Ipsen | 96 | 2004-11-01 | 2019-07-29 |
| Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes sertraline, Placebo - Cerebrovascular Accident, Depression | Phase 4 | Terminated | University of Pittsburgh | 154 | 2004-07-01 | 2014-06-27 |
| Vasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke Atorvastatin - Cerebrovascular Accident, Hypercholesterolemia | Phase 4 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 128 | 2003-06-01 | 2021-02-18 |
| Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke Galantamine, Donepezil - Cerebrovascular Accident | Phase 4 | Completed | University of Pittsburgh | 40 | 2003-04-01 | 2017-12-11 |
| Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity Botulinum toxin type A, Placebo - Muscle Spasticity, Cerebrovascular Accident | Phase 4 | Completed | Ipsen | 162 | 2003-02-01 | 2019-07-26 |
| Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST) Atorvastatin (Lipitor) - Coronary Arteriosclerosis, Diabetes Mellitus, Type 2 | Phase 4 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2080 | 2003-01-01 | 2021-02-18 |
| Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets Atorvastatin (Lipitor) - Coronary Arteriosclerosis, Diabetes Mellitus, Type 2 | Phase 4 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 595 | 2003-01-01 | 2021-02-18 |
| A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels Atorvastatin - Cardiovascular Disease, Cerebrovascular Accident | Phase 4 | Completed | Pfizer | 8600 | 1998-04-01 | 2007-05-03 |
| CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events Atorvastatin - Major Coronary Event, Cerebrovascular Accident | Phase 4 | Completed | Pfizer | 2800 | 1997-01-01 | 2007-05-10 |
Stroke (16) · Coronary Artery Disease (2) · Diabetes Mellitus, Type 2 (2) · Dyslipidemias (2) · Muscle Spasticity (2) · Peripheral Vascular Diseases (2) · Angina, Unstable (1) · Aphasia (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Death (1) · Depression (1) · Hemorrhage (1) · Hypercholesterolemia (1) · Ischemic Stroke (1)
Brain Diseases (16) · Central Nervous System Diseases (16) · Cerebrovascular Disorders (16) · Nervous System Diseases (16) · Vascular Diseases (16) · Cardiovascular Diseases (15) · Heart Diseases (5) · Myocardial Ischemia (5) · Pathological Conditions, Signs and Symptoms (5) · Neurologic Manifestations (4) · Signs and Symptoms (4) · Lipid Metabolism Disorders (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Arterial Occlusive Diseases (2)
Atorvastatin (5) · Botulinum Toxins, Type A (2) · abobotulinumtoxinA (2) · Acenocoumarol (1) · Clopidogrel (1) · Donepezil (1) · Galantamine (1) · Levodopa (1) · Methylphenidate (1) · Sertraline (1) · Standard of Care (1) · Ticagrelor (1) · candesartan (1)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (3) · Ipsen (2) · Pfizer (2) · University of Pittsburgh (2) · Boehringer Ingelheim (1) · Chonnam National University Hospital (1) · City Hospitals Sunderland NHS Foundation Trust (1) · Peking University Third Hospital (1) · Semmelweis University Heart and Vascular Center (1) · University Hospital Muenster (1) · University of Aarhus (1)
United Kingdom (4) · Germany (3) · United States (3) · Australia (2) · Canada (2) · France (2) · Hungary (2) · Ireland (2) · Italy (2) · Spain (2) · Switzerland (2) · Austria (1) · Belgium (1) · Cameroon (1) · China (1)
Caterina Breitenstein, PhD (1) · Christopher S Gray, MD (1) · Ellen M Whyte, MD (1) · Eric J. Lenze, MD (1) · Jakob U Blicher, MD (1) · Myung Ho Jeong, PhD (1) · Ronak Rajani, MD MRCP BM (1) · Stefan Knecht, MD (1) · Xiaogang Li (1)
PMID 27513651, PMID 28573499, PMID 30571333, PMID 31020900, PMID 38018702, PMID 17065671, PMID 17084252, PMID 17626713, PMID 17898099, PMID 18402899, PMID 18482661, PMID 18667813, PMID 18674471, PMID 18777490, PMID 18972097, PMID 19217176, PMID 19286582, PMID 19410683, PMID 19540640, PMID 20060783, PMID 20111849, PMID 20130232, PMID 21185503, PMID 21610204, PMID 22135385, PMID 22368281, PMID 22371239, PMID 22461416, PMID 22575316, PMID 22576673, PMID 23674398, PMID 25531109, PMID 25588456, PMID 25835440, PMID 25899452, PMID 27174798, PMID 28214794, PMID 28379800, PMID 29358194, PMID 29618599, PMID 29622600, PMID 32756984, PMID 35548439, PMID 35915181, PMID 36168113
K23MH064196 (1), K23MH067710 (1)